Gérard Tobelem
Director/Board Member at OSE IMMUNOTHERAPEUTICS
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Dominique Costantini | M | 69 | 20 years | |
Anne-Laure Autret-Cornet | F | - | 8 years | |
Maryvonne Hiance | F | 75 | 8 years | |
Stéphane Silvente | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 6 years |
Emile Loria | M | 74 |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 7 years |
Nicolas Poirier | M | 42 | 8 years | |
Didier Hoch | M | 68 | 8 years | |
Alexandre LeBeaut | M | 66 | 2 years | |
Laurence de Schoulepnikoff | F | - | 3 years | |
Eric Jean Marie Leire | M | 66 | 1 years | |
Philippe Lefèbvre | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | 6 years |
Brigitte Dreno | M | 71 | 7 years | |
Elsy Boglioli Hofman | F | 42 | 3 years | |
Sophie Fay | F | - | - | |
Caroline Thielen | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Silvia Comis | M | - | 3 years | |
Thomas Guillot | M | - | - | |
Sylvie Détry | F | - | - | |
Françoise Bono | M | - | 3 years | |
Patrick Stragier | M | - |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Jean-Michel Foidart | M | 75 |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | - |
Linda Lebon | F | 58 | 3 years | |
Jean-Pascal Conduzorgues | M | - | - | |
Jean Jacques Mention | M | - | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Alexis Peyroles | M | - | 6 years | |
Philippe Pouletty | M | 65 | 8 years | |
Walter Flamenbaum | M | 81 | 6 years | |
Jean-Patrick Demonsang | M | 71 | 9 years | |
Sophie Brouard | M | 53 | - | |
Dominique Takizawa | F | 67 | - | |
Bernard Vanhove | M | - | 2 years | |
Jean-Paul Prieels | M | 78 | 4 years | |
Guy Chatelain | M | - | 6 years | |
Julien Perrier | M | - | - | |
Roland Carbonnel | M | - | 3 years | |
Diane Jorkasky | M | 72 | - | |
Eric Sallen | M | - | 2 years | |
David de Weese | M | 82 | 3 years | |
Antoine Pau | M | - | - | |
Vincent Fert | M | - | 6 years | |
Jean Théron | M | - | 5 years | |
Gerard A. Tardy | M | - | - | |
Alexis Vandier | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
France | 38 | 88.37% |
Belgium | 6 | 13.95% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gérard Tobelem
- Personal Network